Analysts Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.83 Per Share

Equities analysts expect that Recro Pharma Inc (NASDAQ:REPH) will announce earnings of ($0.83) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Recro Pharma’s earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.75). Recro Pharma reported earnings per share of ($0.65) in the same quarter last year, which indicates a negative year-over-year growth rate of 27.7%. The business is scheduled to announce its next earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Recro Pharma will report full year earnings of ($2.96) per share for the current year, with EPS estimates ranging from ($3.15) to ($2.76). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.51) per share, with EPS estimates ranging from ($2.29) to ($0.64). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Recro Pharma.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.17. The firm had revenue of $17.78 million for the quarter, compared to the consensus estimate of $16.01 million. Recro Pharma had a negative return on equity of 472.58% and a negative net margin of 103.07%.



Several research firms recently issued reports on REPH. Zacks Investment Research downgraded Recro Pharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 23rd. Oppenheimer set a $18.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, February 20th. Janney Montgomery Scott restated a “buy” rating and set a $13.00 price target on shares of Recro Pharma in a report on Thursday, January 31st. Finally, ValuEngine downgraded Recro Pharma from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $11.85.

Shares of REPH stock traded down $0.05 on Thursday, hitting $9.01. The stock had a trading volume of 131,586 shares, compared to its average volume of 157,888. The company has a current ratio of 2.45, a quick ratio of 2.08 and a debt-to-equity ratio of 4.04. The company has a market capitalization of $201.23 million, a PE ratio of -3.62 and a beta of -0.30. Recro Pharma has a 1 year low of $4.78 and a 1 year high of $13.05.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its holdings in Recro Pharma by 5.7% during the 4th quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock worth $8,199,000 after purchasing an additional 62,787 shares during the period. Renaissance Technologies LLC boosted its position in shares of Recro Pharma by 26.0% during the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after acquiring an additional 99,200 shares in the last quarter. Engine Capital Management LP boosted its position in shares of Recro Pharma by 21.0% during the 3rd quarter. Engine Capital Management LP now owns 473,484 shares of the specialty pharmaceutical company’s stock worth $3,366,000 after acquiring an additional 82,177 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Recro Pharma by 29.5% during the 3rd quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after acquiring an additional 66,062 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its position in shares of Recro Pharma by 1.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock worth $1,830,000 after acquiring an additional 4,833 shares in the last quarter. Institutional investors own 56.68% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Further Reading: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply